Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D00NVC
|
|||
Former ID |
DNC004042
|
|||
Drug Name |
Z-Ala-Leu-Nal-Agly-Ile-Val-OMe
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1] | |
Structure |
Download2D MOL |
|||
Formula |
C43H59N7O9
|
|||
Canonical SMILES |
CCC(C)C(C(=O)NC(C(C)C)C(=O)OC)NC(=O)NNC(=O)C(CC1=CC=CC2=CC=CC=C21)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)OCC3=CC=CC=C3
|
|||
InChI |
1S/C43H59N7O9/c1-9-27(6)36(40(54)47-35(26(4)5)41(55)58-8)48-42(56)50-49-39(53)34(23-31-20-15-19-30-18-13-14-21-32(30)31)46-38(52)33(22-25(2)3)45-37(51)28(7)44-43(57)59-24-29-16-11-10-12-17-29/h10-21,25-28,33-36H,9,22-24H2,1-8H3,(H,44,57)(H,45,51)(H,46,52)(H,47,54)(H,49,53)(H2,48,50,56)
|
|||
InChIKey |
KMJURIDKPLGXEZ-UHFFFAOYSA-N
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Cathepsin B (CTSB) | Target Info | Inhibitor | [1] |
Cathepsin K (CTSK) | Target Info | Inhibitor | [1] | |
KEGG Pathway | Lysosome | |||
Antigen processing and presentation | ||||
Osteoclast differentiation | ||||
Toll-like receptor signaling pathway | ||||
Rheumatoid arthritis | ||||
NetPath Pathway | TCR Signaling Pathway | |||
IL2 Signaling Pathway | ||||
TGF_beta_Receptor Signaling Pathway | ||||
RANKL Signaling Pathway | ||||
Reactome | Collagen degradation | |||
Trafficking and processing of endosomal TLR | ||||
Assembly of collagen fibrils and other multimeric structures | ||||
MHC class II antigen presentation | ||||
Degradation of the extracellular matrix | ||||
Activation of Matrix Metalloproteinases | ||||
WikiPathways | RANKL/RANK Signaling Pathway | |||
Osteoclast Signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Azapeptides structurally based upon inhibitory sites of cystatins as potent and selective inhibitors of cysteine proteases. J Med Chem. 2002 Sep 12;45(19):4202-11. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.